One IBD medicine can have a generic name, brand name, drug class and target. A short clinic letter can therefore sound like it lists several medicines when it is describing one.
Start with the class. It tells you the medicine's broad job, not whether it is right for you. Medicines in the same class can still differ in how they are given, where they act and what needs monitoring.
The aim is usually to control inflammation and keep it controlled without steroids. Symptoms matter too, but feeling better and controlling bowel inflammation are not always the same thing.
Mirae can turn a medication list into a treatment map: what each medicine is for, how it is taken, what needs monitoring and which question comes next. It does not choose or assess treatment.
Some medicines gain control; others keep it
Induction treatment brings active disease under control. Maintenance treatment aims to stop inflammation returning. One medicine may do both jobs; another may bridge the time before a slower treatment begins to work.
This is why a steroid may help during a flare but not belong in the long-term plan, and why a maintenance medicine may continue after symptoms settle.
| Medication class | Broad action | Common forms |
|---|---|---|
| 5-ASAs | Reduce inflammation at the bowel lining, mainly in ulcerative colitis | Tablets, granules, suppositories or enemas |
| Corticosteroids | Reduce inflammation quickly for short-term control | Tablets, rectal treatment, injections or infusions |
| Immunomodulators | Change immune activity more broadly and slowly | Tablets or injections |
| Biologics | Block a selected inflammatory target or process | Injections or infusions |
| Targeted oral medicines | Block selected immune signals or immune-cell movement | Tablets or capsules |
This is a map, not a treatment ladder. Current ulcerative colitis guidance and current Crohn's disease guidance support earlier use of advanced treatment for many people with moderate-to-severe disease. You do not necessarily move through every row first.
5-ASAs act mainly at the bowel lining
5-ASAs such as mesalazine and sulfasalazine act at the bowel lining. They are used mainly for mild-to-moderate ulcerative colitis; their role in Crohn's disease is much more limited.
Tablets and granules release medicine in different parts of the bowel. Suppositories and enemas deliver it to the rectum or lower colon. Oral and rectal treatment may be combined when disease location makes that useful.
Products and formulations are not automatically interchangeable. Keep the exact name and form in your medication record, and ask before substituting one product for another.
Corticosteroids are a short-term tool
Corticosteroids such as prednisolone, hydrocortisone and budesonide can reduce inflammation quickly. Depending on disease location and severity, they may be taken by mouth, used rectally or given in hospital.
Steroids can bring a flare under control, but they are not maintenance medicines. The chance of important side effects rises with longer or repeated use, so the long-term aim is remission without them.
Do not stop oral steroids suddenly without advice, invent a taper or restart leftovers for new symptoms. Follow the current written schedule and contact the prescribing service when it is unclear.
Immunomodulators work more slowly
Thiopurines such as azathioprine and mercaptopurine, and methotrexate, alter immune activity more broadly than medicines aimed at one target. They usually take time to have an effect.
Depending on the diagnosis and plan, they may maintain remission or be used alongside some biologics. They are not interchangeable: the evidence for methotrexate, for example, differs between Crohn's disease and ulcerative colitis.
Blood tests before and during treatment monitor blood cells and the liver. Infection, vaccination, pregnancy, fertility and surgery questions need advice for the specific medicine, not the class alone.
Biologics block a selected target
Biologics are protein medicines, usually antibodies, that block a selected part of inflammation. The main groups used in IBD include:
- Anti-TNF medicines, which block tumour necrosis factor, an inflammatory signalling protein.
- Anti-integrin medicines, which limit the movement of certain immune cells into the gut.
- Interleukin inhibitors, which block selected signalling pathways such as IL-12/23 or IL-23.
Biologics are given by infusion or injection; some begin with an infusion and continue as injections. A biosimilar is a version assessed against an existing biologic, not a weaker medication class.
The target is only one part of the choice. Prior treatment, disease location and complications, other health conditions, safety, pregnancy plans, preferred form and access may all matter.
Targeted oral medicines are small molecules
Small-molecule medicines are taken by mouth. JAK inhibitors block enzymes that pass inflammatory signals inside cells. S1P receptor modulators change how certain white blood cells move around the body.
A tablet is not automatically milder or safer than an injection. These medicines have specific screening, interaction and monitoring needs. European safety advice for JAK inhibitors highlights how age, smoking history and risks of infection, cancer, blood clots or cardiovascular disease may affect whether a JAK inhibitor is suitable.
Other medicines may support a specific problem
Not every medicine on an IBD list controls IBD itself. Antibiotics may treat an infection or complication; iron, vitamins or electrolytes may replace a deficiency; and symptom medicines may help pain, nausea, constipation or diarrhoea without treating inflammation.
Specialist rescue medicines such as calcineurin inhibitors may be used in hospital for acute severe ulcerative colitis. Nutrition therapy and surgery may also be central to IBD care, although they are not medication classes.
Ask what job each item is doing. Symptom relief does not show that inflammation is controlled, and some symptom medicines may be unsuitable during a severe flare or complication.
Monitoring is part of the treatment
Monitoring answers two different questions: is treatment safe, and is inflammation controlled? The team may check vaccinations and infection risk before treatment, then use blood tests, symptoms, stool markers, colonoscopy or imaging. The plan depends on the medicine.
A normal safety blood test does not show that the bowel has healed. A lower calprotectin does not prove that a medicine is safe. The guide to IBD tests and markers explains which questions common results can answer.
For some biologics, the team may check medicine and antibody levels when response is lost or dosing is reviewed. These results need medicine-specific interpretation.
Why one class may fit better than another
Treatment choice may bring together:
- the diagnosis, location and severity of IBD, including any complications
- how quickly inflammation needs to be controlled
- previous response, side effects or loss of response
- infection risk, other health conditions and other medicines
- age, vaccinations, pregnancy and fertility considerations
- which form, monitoring plan and access route are workable
Another person's successful medicine may therefore be unsuitable for you. A more targeted-sounding medicine is not automatically the better choice.
Turn your medicine list into a treatment map
A medicine name is not enough. In Mirae, keep its job, schedule, monitoring and next review beside symptoms and questions. This makes a treatment change easier to explain at an appointment, but Mirae does not prescribe, check interactions or decide whether a medicine is working.
Template: copy it, then fill in your own answers
Name on my label:
Generic and brand names, if known:
Class:
Job: induction, maintenance or symptom support
How and when I take it:
Started:
Monitoring and next due date:
When response will be reviewed:
Problems I was told to report:
Who to contact about this medicine:
Next review or question:Before starting or changing treatment, useful questions include:
- What is the goal, and how will we know whether it is working?
- How soon might it work, and what is the plan while we wait?
- Which tests, vaccines or checks are needed?
- Which problems need prompt advice, and what should I do about a late or missed dose?
- How do pregnancy, surgery or travel change the plan?
- Who should I contact, and when would we reconsider the medicine?
Save the confirmed answers in Mirae as part of your IBD medication record. Missed-dose and stopping instructions differ by medicine, so use the current patient information leaflet and prescribing team rather than a general class description.
Medical and product note
This guide provides general information for adults living with IBD. It does not recommend a medication, compare individual products or provide dosing, interaction, pregnancy or side-effect advice. Available treatments and approvals vary by country and can change.
Mirae can organise medicine information and questions, but it does not prescribe, reconcile medicines or recommend treatment changes, and its AI can be incomplete or wrong. Do not start, stop or change prescribed treatment without medicine-specific advice.
References
- Gordon W. Moran et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut, 2025.
- Siddharth Singh et al. Living guideline for pharmacological management of moderate-to-severe ulcerative colitis. American Gastroenterological Association, 2024; evidence reviewed 2026.
- Frank I. Scott et al. Pharmacological management of moderate-to-severe Crohn's disease. American Gastroenterological Association, 2025; evidence reviewed 2026.
- National Institute for Health and Care Excellence. Ulcerative colitis: management. NICE, 2019.
- National Institute for Health and Care Excellence. Crohn's disease: management. NICE, 2019.
- National Health Service. Steroids. NHS, 2025.
